New England Eye Center, Tufts University School of Medicine, Boston, Massachusetts.
New England Eye Center, Tufts University School of Medicine, Boston, Massachusetts2Ophthalmic Epidemiology and Genetics Service, Department of Ophthalmology, Tufts University School of Medicine, Boston, Massachusetts.
JAMA Ophthalmol. 2015 Jul;133(7):785-91. doi: 10.1001/jamaophthalmol.2015.0814.
The complement factor H R1210C rare variant confers the strongest genetic risk for age-related macular degeneration and earlier age at onset; however, its associated phenotype has not been well characterized.
To describe specific fundus features of a white population with the R1210C rare variant.
DESIGN, SETTING, AND PARTICIPANTS: Fundus features specific for diagnosis and disease staging were retrospectively characterized by systematic review of all available fundus images for each patient, including color photography, fluorescein angiography, fundus autofluorescence, and optical coherence tomography, at a tertiary ophthalmologic referral center. For this retrospective observational study conducted from 2012 to 2014, enrolled patients with the variant and their family members without the variant were identified from the Age-Related Macular Degeneration Study for a family-based study arm. For patients with the variant but without a family member enrolled in the study, age-matched comparison individuals without the variant were selected randomly from the database.
The presence of drusen in the macula (macular drusen score) and estimated number (total macular drusen score) were assessed. The presence of drusen in the extramacular regions (extramacular drusen score), pigmentary abnormalities, and disease staging were also evaluated. Binary logistic regression models were used to evaluate the association between rare variant status and ocular phenotypes.
Images from a total of 143 patients (283 eyes), including 62 patients with the rare variant, were analyzed. Drusen score covariates were associated with the R1210C rare variant. A larger proportion of patients carrying the variant had the highest level of macular and total macular drusen scores compared with those without the variant (57.9% vs 16.7% and 52.9% vs 14.2%, respectively; P for trend < .001 for both scores). Patients carrying the rare variant had a much greater likelihood of having advanced disease (odds ratio, 7.0; 95% CI, 3.1-16.2; P < .001). A higher prevalence of geographic atrophy was observed among patients carrying the variant (odds ratio, 13.7; 95% CI, 5.0-37.7; P < .001).
The typical phenotype of the complement factor H R1210C rare variant is associated with extensive drusen accumulation in the macula and throughout the fundus, as well as with a high risk for having advanced disease. Better characterization of genetic profiles in age-related macular degeneration may be important for screening and future therapeutic strategies for this vision-threatening condition.
补体因子 H R1210C 稀有变异赋予了与年龄相关的黄斑变性和发病年龄更早最强的遗传风险;然而,其相关表型尚未得到很好的描述。
描述携带 R1210C 稀有变异的白种人群的特定眼底特征。
设计、地点和参与者:在一家三级眼科转诊中心,通过对每位患者的所有可用眼底图像(包括彩色摄影、荧光素血管造影、眼底自发荧光和光学相干断层扫描)进行系统回顾,回顾性地描述了用于诊断和疾病分期的特定眼底特征。对于这项 2012 年至 2014 年进行的回顾性观察性研究,通过家族研究臂,从年龄相关性黄斑变性研究中确定了携带变异体的患者及其无变异体的家族成员。对于携带变异体但无家族成员参加研究的患者,从数据库中随机选择无变异体的年龄匹配比较个体。
评估黄斑区(黄斑区玻璃膜疣评分)和估计数量(总黄斑区玻璃膜疣评分)的玻璃膜疣存在情况。还评估了玻璃膜疣以外区域(玻璃膜疣以外评分)、色素异常和疾病分期的存在情况。二元逻辑回归模型用于评估稀有变异体状态与眼部表型之间的关联。
共分析了 143 名患者(283 只眼)的图像,包括 62 名携带稀有变异体的患者。玻璃膜疣评分协变量与 R1210C 稀有变异体相关。与不携带变异体的患者相比,携带变异体的患者有更高比例的患者具有最高水平的黄斑和总黄斑玻璃膜疣评分(分别为 57.9%比 16.7%和 52.9%比 14.2%;两个评分的趋势 P<0.001)。携带罕见变异体的患者发生晚期疾病的可能性要大得多(优势比,7.0;95%置信区间,3.1-16.2;P<0.001)。携带变异体的患者中观察到更高的地图状萎缩患病率(优势比,13.7;95%置信区间,5.0-37.7;P<0.001)。
补体因子 H R1210C 稀有变异的典型表型与黄斑区和眼底广泛的玻璃膜疣积聚以及晚期疾病风险增加有关。更好地描述年龄相关性黄斑变性的遗传特征对于这种威胁视力的疾病的筛查和未来的治疗策略可能很重要。